肺移植术后淋巴组织增生性疾病的研究进展  

Research progress on posttransplant lymphoproliferative disease after lung transplantation

作　　者：班乐 张稷 周敏 王红梅 毛文君 陈静瑜 Ban Le;Zhang Ji;Zhou Min;Wang Hongmei;Mao Wenjun;Chen Jingyu(Department of Lung Transplantation,Wuxi People's Hospital Affiliated to Nanjing Medical University,Wuxi 214000,China;不详)

机构地区：[1]南京医科大学附属无锡人民医院肺移植科,江苏无锡214000 [2]南京医科大学附属无锡人民医院胸外科,江苏无锡214000

出　　处：《器官移植》2021年第5期607-613,共7页Organ Transplantation

基　　金：江苏省科教强卫工程青年医学重点人才项目(QNRC2016193)。

摘　　要：移植后淋巴组织增生性疾病(PTLD)是肺移植术后可致死性并发症,与年龄、免疫抑制水平、爱泼斯坦-巴尔病毒(EBV)感染等密切相关。降低免疫抑制水平、利妥昔单抗治疗、T细胞免疫治疗是其常见的治疗手段。随着肺移植在中国的迅速发展,肺移植术后PTLD也引起高度关注。本文就肺移植术后发生PTLD的危险因素、病理分型、临床表现、诊断、治疗、预后和预防做一综述,旨在为肺移植术后PTLD发生、发展的早期监测和管理提供参考。Posttransplant lymphoproliferative disease(PTLD)is a fatal complication after lung transplantation,which is intimately associated with age,immunosuppression level and Epstein-Barr virus(EBV)infection,etc.Reducing immunosuppression level,rituximab therapy and T cell immunotherapy are common treatments for PTLD.With the rapid development of lung transplantation in China,PTLD after lung transplantation has attracted widespread attention.This article reviews the risk factors,pathological types,clinical manifestations,diagnosis,treatment,prognosis and prevention of PTLD after lung transplantation,aiming to provide reference for early monitoring and management of the incidence and progression of PTLD.

关 键 词：肺移植 慢性移植肺功能障碍(CLAD) 移植后淋巴组织增生性疾病(PTLD) 爱泼斯坦-巴尔病毒(EBV) 免疫抑制 利妥昔单抗 移植物抗宿主病(GVHD) 闭塞性细支气管炎综合征 

分 类 号：R617[医药卫生—外科学] R563[医药卫生—临床医学]